A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
NCT ID: NCT07129252
Last Updated: 2026-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
150 participants
INTERVENTIONAL
2025-11-26
2029-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma
NCT06384482
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
NCT06440057
A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid Tumors
NCT06172309
An Exploratory Study of Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV in Advanced Solid Tumor Treatment
NCT06497010
A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors
NCT06300216
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose Escalation
Multiple Dose Levels administered Q3W
CRN09682
Study drug CRN09682 intravenously
Dose Expansion: Cohort 1
Pancreatic Neuroendocrine Tumor (NET)
CRN09682
Study drug CRN09682 intravenously
Dose Expansion: Cohort 2
Non-Pancreatic NET
CRN09682
Study drug CRN09682 intravenously
Dose Expansion: Cohort 3
Neuroendocrine Carcinoma (NEC)
CRN09682
Study drug CRN09682 intravenously
Dose Expansion: Cohort 4
Other Solid Tumors
CRN09682
Study drug CRN09682 intravenously
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CRN09682
Study drug CRN09682 intravenously
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have one or more measurable disease location per RECIST version 1.1.
* Have a tumor that expresses SSR confirmed by SSR imaging.
* Have an ECOG performance status of 0, 1, or 2.
Exclusion Criteria
* Have brain metastases unless asymptomatic and stable for at least one month for participants with SCLC or LCLC or at least 3 months for participants with other non-NET solid tumors.
* Use of anticancer agents within specified intervals prior to the first dose of study drug.
* Had surgery, chemoembolization, or radiofrequency ablation within 90 days prior to first dose of study drug.
* Prior participation in any intervention clinical study within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug.
* Participants with carcinoid syndrome.
* Secondary malignancy: participants who have any other malignancy known to be active or treated within 3 years of the start of screening, with the exception of treated cervical intraepithelial neoplasia, superficial (noninvasive) bladder cancer, and non-melanoma skin cancer.
* Have prior treatment with MMAE.
* Have hypersensitivity or history of anaphylactic reaction to octreotide, other SSAs, and/or MMAE.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Crinetics Pharmaceuticals Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Crinetics Study Site
Denver, Colorado, United States
Crinetics Study Site
Duarte, California, United States
Crinetics Study Site
Newport Beach, California, United States
Crinetics Study Site
New Haven, Connecticut, United States
Crinetics Study Site
Atlanta, Georgia, United States
Crinetics Study Site
Lexington, Kentucky, United States
Crinetics Study Site
Metairie, Louisiana, United States
Crinetics Study Site
Grand Rapids, Michigan, United States
Crinetics Study Site
Philadelphia, Pennsylvania, United States
Crinetics Study Site
Austin, Texas, United States
Crinetics Study Site
Houston, Texas, United States
Crinetics Study Site
Irving, Texas, United States
Crinetics Study Site
Salt Lake City, Utah, United States
Crinetics Study Site
Charlottesville, Virginia, United States
Crinetics Study Site
Fairfax, Virginia, United States
Crinetics Study Site
Barcelona, , Spain
Crinetics Study Site
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRN09682-191
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.